| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36c946bd4dc810605e633f0aead2bece |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 |
| filingDate |
2012-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac1783f3305cdaaa37856ba1f9b66342
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcdec24bde518076f330c8ce1249c3d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aee9dfb9c1a804519dfc83046ec1f9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ef0fdfa46f1ded652f8c5a8d5c5439f |
| publicationDate |
2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2671575-C2 |
| titleOfInvention |
Appliance of solifenacin and saliva flow stimulators for the treatment of overactive bladder |
| abstract |
FIELD: medicine. n SUBSTANCE: group of inventions relates to medicine and can be used to alleviate a side effect of treatment with solifenacin in a patient. Therapeutically effective amount of extended release solifenacin or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of pilocarpine or a pharmaceutically acceptable salt thereof, are used. Pilocarpine or a pharmaceutically acceptable salt thereof, is administrated to the patient about 2 hours after the administration of solifenacin or a pharmaceutically acceptable salt thereof. Method of treating a patient suffering from overactive bladder and a method of alleviating a side effect of treatment with solifenacin in a patient, which is dry mouth are also proposed. n EFFECT: group of inventions allows alleviating a side effect of treatment with solifenacin in a patient. n 17 cl, 5 tbl, 3 dwg, 3 ex |
| priorityDate |
2011-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |